Janux Therapeutics surged on promising early data and M&A rumors in 2024, but recent clinical updates led to a sharp stock decline. Click for more on JANX.
Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...
GSK slides 1.82% today to GBX1865.50 despite ongoing progress in oncology and vaccines, with volatility remaining elevated.
Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and ...
Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise.
The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...
Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.
Merck Announce Clinical Collaboration and Supply Agreement to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors CI Sep. 14 Perspective Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results